Maze Therapeutics (NASDAQ:MAZE) Shares Gap Down – Time to Sell?

Maze Therapeutics, Inc. (NASDAQ:MAZE) gapped down before the market opened on Thursday . The stock had previously closed at $29.58, but opened at $28.40. Maze Therapeutics shares last traded at $28.0550, with a volume of 56,132 shares trading hands.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Maze Therapeutics in a research note on Wednesday, June 24th. Wall Street Zen downgraded shares of Maze Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. TD Cowen raised shares of Maze Therapeutics to a “strong-buy” rating in a report on Monday. Finally, BTIG Research reaffirmed a “buy” rating and set a $46.00 price target on shares of Maze Therapeutics in a research report on Wednesday, August 12th. Three analysts have rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $66.00.

Maze Therapeutics Stock Performance

The firm’s 50 day moving average price is $28.64 and its 200-day moving average price is $32.04. The company has a debt-to-equity ratio of 0.09, a quick ratio of 18.31 and a current ratio of 18.31. The firm has a market capitalization of $1.58 billion, a PE ratio of -11.25 and a beta of 2.21.

Maze Therapeutics (NASDAQ:MAZE) last posted its earnings results on Tuesday, August 11th. The company reported ($0.76) EPS for the quarter, meeting analysts’ consensus estimates of ($0.76). On average, research analysts expect that Maze Therapeutics, Inc. will post -2.72 EPS for the current year.

Insider Buying and Selling at Maze Therapeutics

In other Maze Therapeutics news, CMO Harold Bernstein sold 16,142 shares of the company’s stock in a transaction on Thursday, August 13th. The shares were sold at an average price of $27.61, for a total transaction of $445,680.62. Following the completion of the transaction, the chief marketing officer directly owned 16,142 shares in the company, valued at approximately $445,680.62. This represents a 50.00% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Atul Dandekar sold 7,500 shares of the company’s stock in a transaction dated Wednesday, July 29th. The stock was sold at an average price of $27.34, for a total transaction of $205,050.00. Following the transaction, the insider owned 26,250 shares of the company’s stock, valued at approximately $717,675. This trade represents a 22.22% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 108,110 shares of company stock valued at $3,057,531. Company insiders own 5.30% of the company’s stock.

Institutional Investors Weigh In On Maze Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada boosted its stake in Maze Therapeutics by 128.3% during the fourth quarter. Royal Bank of Canada now owns 646 shares of the company’s stock worth $27,000 after buying an additional 363 shares during the last quarter. Ameritas Investment Partners Inc. lifted its position in Maze Therapeutics by 82.6% in the third quarter. Ameritas Investment Partners Inc. now owns 1,632 shares of the company’s stock valued at $42,000 after buying an additional 738 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Maze Therapeutics during the 4th quarter worth approximately $43,000. Mitsubishi UFJ Asset Management Co. Ltd. purchased a new position in shares of Maze Therapeutics during the second quarter worth $48,000. Finally, Russell Investments Group Ltd. boosted its holdings in Maze Therapeutics by 947.8% during the 3rd quarter. Russell Investments Group Ltd. now owns 1,907 shares of the company’s stock valued at $49,000 after acquiring an additional 1,725 shares during the period.

About Maze Therapeutics

Maze Therapeutics, Inc (NASDAQ: MAZE) is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics by leveraging insights from human genetics and genomics. The company applies advanced data analytics and proprietary platforms to identify targets with strong genetic validation, aiming to de‐risk early drug discovery and accelerate the development of medicines for patients with serious diseases. Maze’s approach centers on translating naturally occurring human mutations into a deeper understanding of disease biology, with an emphasis on validating therapeutic hypotheses before advancing into the clinic.

Since its inception, Maze has assembled a diversified pipeline of programs across metabolic, immunological and other therapeutic areas.